BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 17535009)

  • 1. OFT, VBP: QED?
    Claxton K
    Health Econ; 2007 Jun; 16(6):545-58. PubMed ID: 17535009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug price reform in the UK: debunking the myths.
    Thornton S
    Health Econ; 2007 Oct; 16(10):981-92. PubMed ID: 17853505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Straight talk with... Mark Sculpher. Interview by Kate Ravilious.
    Sculpher M
    Nat Med; 2012 Sep; 18(9):1315. PubMed ID: 22961148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmaceutical reference pricing in Germany: definition of therapeutic groups, price setting through regression procedure and effects].
    Stargardt T; Schreyögg J; Busse R
    Gesundheitswesen; 2005 Jul; 67(7):468-77. PubMed ID: 16103970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. If it ain't broke, don't price fix it: the OFT and the PPRS.
    Towse A
    Health Econ; 2007 Jul; 16(7):653-65. PubMed ID: 17595047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does the UK National Health Service need a fourth hurdle for pharmaceutical reimbursement to encourage the more efficient prescribing of pharmaceuticals?
    Freemantle N
    Health Policy; 1999 Mar; 46(3):255-65. PubMed ID: 10351671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Office of Fair Trading report: a prescription for value-based drug pricing.
    Minhas R; Moon JC
    J R Soc Med; 2007 May; 100(5):216-8. PubMed ID: 17470928
    [No Abstract]   [Full Text] [Related]  

  • 8. Value based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong?
    Towse A
    Br J Clin Pharmacol; 2010 Sep; 70(3):360-6. PubMed ID: 20716236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The UK pharmaceutical market. An overview.
    Towse A
    Pharmacoeconomics; 1996; 10 Suppl 2():14-25. PubMed ID: 10163432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new reimbursement system for innovative pharmaceuticals combining value-based and free market pricing.
    Persson U; Svensson J; Pettersson B
    Appl Health Econ Health Policy; 2012 Jul; 10(4):217-25. PubMed ID: 22676213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The simple economics of risk-sharing agreements between the NHS and the pharmaceutical industry.
    Barros PP
    Health Econ; 2011 Apr; 20(4):461-70. PubMed ID: 21394816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. UK budgetary systems and new health-care technologies.
    McGuire A; Litt M
    Value Health; 2003; 6 Suppl 1():S64-73. PubMed ID: 12846927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How Medicare could get better prices on prescription drugs.
    Outterson K; Kesselheim AS
    Health Aff (Millwood); 2009; 28(5):w832-41. PubMed ID: 19643778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug prices and value for money: the Australian Pharmaceutical Benefits Scheme.
    Henry DA; Hill SR; Harris A
    JAMA; 2005 Nov; 294(20):2630-2. PubMed ID: 16304078
    [No Abstract]   [Full Text] [Related]  

  • 15. Value based pricing for NHS drugs: an opportunity not to be missed?
    Claxton K; Briggs A; Buxton MJ; Culyer AJ; McCabe C; Walker S; Sculpher MJ
    BMJ; 2008 Feb; 336(7638):251-4. PubMed ID: 18244997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pricing and reimbursement of drugs in Ireland.
    Barry M; Tilson L; Ryan M
    Eur J Health Econ; 2004 Jun; 5(2):190-4. PubMed ID: 15452757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The high cost of medicines in Ireland. Is it time to change the pricing mechanism?
    Tilson L; McGowan B; Bennett K; Barry M
    Eur J Health Econ; 2004 Dec; 5(4):341-4. PubMed ID: 15452737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Competition in the NHS internal market: an overview of its effects on hospital prices and costs.
    Propper C; Söderlund N
    Health Econ; 1998 May; 7(3):187-97. PubMed ID: 9639333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden.
    Persson U; Willis M; Odegaard K
    Eur J Health Econ; 2010 Apr; 11(2):195-203. PubMed ID: 19639352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methodological aspects of international drug price comparisons.
    Andersson F
    Pharmacoeconomics; 1993 Oct; 4(4):247-56. PubMed ID: 10146914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.